Modified tuberculosis vaccine as therapy against bladder cancer

March 5, 2020

The Max Planck Insitute for Infection Biology is sharing news of interest to the Immunology Community.

Therapy with VPM1002 is effective in bladder cancer patients

The human immune system can recognize and eliminate not only germs but also cancer cells. This is why treatments with weakened germs can help the immune system it ist fight against cancer.

The Max Planck Insitute for Infection Biology has developed a vaccine against TB which is currently in phase III trial. Less known is that this vaccine is also tested for treatment of bladder cancer and it has now shown a remarkable outcome in a clinical trial in preventing cancer recurrence.

clinical trial no.: NCT02371447 (https://clinicaltrials.gov/ct2/show/NCT02371447)

More News

Scholarships to Attend 21st Spring School on Immunology

October 10, 2025Deutsche Gesellschaft für Immunologie

IUIS 2025 Congress Recordings Now Available on ImmunoHub

September 30, 2025

Highlights from our Junior Community Scientific Symposium

September 26, 2025Early Career Committee (ECC), European Federation of Immunological Societies (EFIS) and 1 more

Opportunities from the International Science Council (ISC)

September 24, 2025

Funding Opportunity: ICLAS invites its members to apply for financial support

September 19, 2025Veterinary Immunology Committee (VIC)

IUIS 2025 Congress Recordings – Coming Soon on Immunohub!

September 9, 2025

IUIS Education Committee Brings You a Symposium

August 8, 2025Education Committee (EDU)

Visit the IUIS Booth at the IUIS 2025 Congress!

July 29, 2025

A message from IUIS President, Dr Miriam Merad

July 2, 2025